Business Context and Reporting Period
This Form 8-K is filed by pSivida Corp. (not Eyepoint, Inc.) for the reporting period ending December 25, 2016. The filing discloses the automatic termination of a material definitive agreement with Pfizer Inc. and the departure of a senior officer.
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial figure disclosed relates to a historical transaction: Pfizer paid pSivida $2.3 million as an upfront payment in June 2011 under the terminated agreement. The agreement had potential consideration of up to $168.8 million plus royalties, which was not realized due to the termination.
Material Changes
- Termination of Pfizer Agreement: The Amended and Restated Collaborative Research and License Agreement with Pfizer automatically terminated on December 26, 2016. This occurred because pSivida delivered a "Cessation Notice" on October 27, 2016, and Pfizer failed to exercise its "Funding Option" within the required 60-day window.
- Intellectual Property Rights: Upon termination, pSivida regained the right to develop, manufacture, and commercialize the Product (a sustained release bioerodible implant for latanoprost) alone or with third parties, subject to necessary Pfizer IP rights.
- Executive Departure: The position of Vice President of Corporate Affairs and General Counsel was eliminated, resulting in the termination of Lori Freedman effective December 26, 2016.
Outlook, Risks, and Management Commentary
Management Action: The company elected to cease development of the Product under the Pfizer agreement to regain full control of the asset.
Compensatory Arrangement: A cooperation agreement was executed with the departing officer, Ms. Freedman, requiring up to 20 hours of cooperation per month in January and February 2017. In exchange, the exercise period for her vested stock options was extended to June 26, 2018.
Risks/Contingencies: The automatic termination is subject to a limited exception: if pSivida does not actually cease all development activities regarding the Product for at least one year, the termination would be null and void.
Investor Verification Checklist
- Verify the current status of the Product's development and whether pSivida has ceased all activities as required to maintain the termination.
- Confirm the specific intellectual property rights retained by Pfizer that may limit pSivida's ability to commercialize the Product independently.
- Review the full text of the Cooperation Agreement (Exhibit 10.1) for any additional financial obligations or non-compete clauses regarding Ms. Freedman.
- Assess the impact of losing the Pfizer partnership on the company's future funding and commercialization strategy.